CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本方案适用于儿童哮喘管理项目继续研究/2期（CAMPCS/2），这是一项对入组儿童哮喘管理项目（CAMP）的儿童进行的3.25年观察性随访研究。 CAMP是一项多中心随机临床试验，旨在确定1041名轻度哮喘儿童（年龄5-13岁，随机分组）在3.5-5.5年治疗期内三种治疗（沙丁胺醇单药治疗、沙丁胺醇联合吸入性皮质类固醇（ICS）治疗、沙丁胺醇联合吸入性非类固醇治疗）对肺功能的影响。 在4.5年的观察期（CAMP延续研究，CAMPCS）中对该队列进行了随访，以确定治疗对肺部的长期影响，并基于国家指南。 CAMPCS/2被设计为在成年早期再随访该队列4年，此时患者将为17-26岁（55% >21岁）。 儿童哮喘可导致成年后的严重肺部疾病，并可能发展为慢性阻塞性肺疾病（COPD）。 儿童哮喘的长期随访研究中，没有一项有确定炎症因子对结果的决定因素所需的密切随访。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is for the Childhood Asthma Management Program Continuation Study/Phase 2 (CAMPCS/2), A 3.25 year observational follow-up study of the children enrolled in the Childhood Asthma Management Program (CAMP). CAMP was a multicenter randomized clinical trial designed to determine the effects of three treatments (albuterol alone, albuterol with inhaled corticosteroid (ICS), albuterol with inhaled non-steroid) in 1041 children (randomized at ages 5-13 years) with mild asthma on pulmonary function during a 3.5-5.5 year treatment phase. The cohort has been followed in a 4.5 year observational phase (CAMP Continuation Study, CAMPCS) to determine longer term effects of the treatments on lung and based on national guidelines. CAMPCS/2 is designed to follow the cohort for 4 additional years in to early adulthood, when the patients will be 17-26 years (55% >21 years). Childhood asthma can result in significant lung disease in adulthood and possibly the development of chronic obstructive pulmonary disease (COPD). None of the long-term follow-up studies of childhood asthma have had the close follow-up needed to define determinants of outcomes in inflammatory agents on outcomes.